Results 151 to 160 of about 4,270,323 (214)

Liver Injury Repair and Regeneration: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 11, November 2026.
This review outlines the spatiotemporal framework of liver injury repair and regeneration, orchestrated by molecular signaling, multicellular niche crosstalk, metabolic reprogramming, and interorgan communication. Post‑injury regenerative cascades (initiation, proliferation, termination) rely on crosstalk between hepatocytes, Kupffer cells, hepatic ...
Mingyue Pan, Ni An, Yutian Feng, Yuelei Hu, Chongqin Pan, Yuxin Su, Yuanzheng Huang, Tanqing Long, Qi Wang, Qingru Song, Pengfei Li, Xiaomeng Li, Wenzhen Yin, Zhiyuan Hu, Xiaoxuan Liu, Juan Liu   +15 more
wiley   +1 more source

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

The Journal of Pathology, Volume 270, Issue 3, Page 380-395, November 2026.
Abstract Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of ...
Matilde Monti, Martina Brigida Romanello, Luca Agnelli, Matteo Orlandi, Luca Bertoli, Sara Picinoli, Irene Pezzali, Giulio Eugenio Mandelli, Daniela Medicina, Giovanni Ribaudo, Adele Busico, Elena Conca, Vilma Pellegrini, Piera Balzarini, Daniele Gallucci, Anna Di Matteo, Davide Lombardi, Claudia Ghigna, Giancarlo Pruneri, Alessandra Gianoncelli, Marzia Rossato, William Vermi   +21 more
wiley   +1 more source

PEBP1, a RAF kinase inhibitory protein, negatively regulates starvation-induced autophagy by direct interaction with LC3. [PDF]

Autophagy, 2016
Noh HS, Hah YS, Zada S, Ha JH, Sim G, Hwang JS, Lai TH, Nguyen HQ, Park JY, Kim HJ, Byun JH, Hahm JR, Kang KR, Kim DR.   +13 more
europepmc   +1 more source

Renin‐Angiotensin Signaling and Vascular Function: Insights into Health and Disease

Acta Physiologica, Volume 242, Issue 11, November 2026.
ABSTRACT The renin‐angiotensin system (RAS) is an essential regulator of vascular structure and function, and dysregulation of angiotensin II (Ang II) signaling plays a critical role in the development of hypertension and associated vascular complications.
Giovanni Bertoldi, Swapnil K. Sonkusare
wiley   +1 more source

Desflurane Increases Hippocampal RAF-MAPK-MSK1 Protein Levels and Reduces CLOCK Expression: Sorafenib Attenuates Cognitive Impairment in Aged Mice. [PDF]

Neurochem Res
Chou C, Jia Y, Zhang X, Bai J, Shang X, Duan X.   +5 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity. [PDF]

Oncotarget, 2016
Noh HS, Hah YS, Ha JH, Kang MY, Zada S, Rha SY, Kang SS, Kim HJ, Park JY, Byun JH, Hahm JR, Shin JK, Jeong SH, Lee YJ, Kim DR.   +14 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, Volume 183, Issue 22, Page 6607-6626, November 2026.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery. [PDF]

Arch Pharm (Weinheim)
Guo XK, Rakesh KP, Raju S, Sharath Kumar KS, Qin HL.   +4 more
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, Volume 117, Issue 11, Page 2901-2909, November 2026.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source